Nick DeVito
@ndevitomd.bsky.social
710 followers
960 following
210 posts
Assistant Prof, GI Oncologist @
Duke Cancer researching immunotherapy, metastasis, and the immune microenvironment.
#FirstGen. USouthFlorida alumnus. Tufts residency survivor.
Patients don’t fail treatments, treatments fail patients.
Opinions=mine
Posts
Media
Videos
Starter Packs
Pinned
Nick DeVito
@ndevitomd.bsky.social
· Feb 24
Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin Signaling - PubMed
Therapeutic resistance to immune checkpoint blockade has been commonly linked to the process of mesenchymal transformation (MT) and remains a prevalent obstacle across many cancer types. An improved m...
pubmed.ncbi.nlm.nih.gov
Reposted by Nick DeVito
Reposted by Nick DeVito
Reposted by Nick DeVito
Reposted by Nick DeVito
Reposted by Nick DeVito
Reposted by Nick DeVito
Immunity
@cp-immunity.bsky.social
· Sep 9
Oxidative-stress-induced telomere instability drives T cell dysfunction in cancer
The functional state of tumor-infiltrating lymphocytes is a critical determinant of antitumor immunity and response to immunotherapy. Rivadeneira et al. demonstrate that mitochondrial ROS accumulation induces oxidative damage at telomeres, which is sufficient to drive T cell dysfunction. Neutralizing ROS at telomeres mitigates T cell dysfunction and improves cellular therapies.
dlvr.it
Nick DeVito
@ndevitomd.bsky.social
· Sep 4
Reposted by Nick DeVito
Kai Ryssdal
@kairyssdal.bsky.social
· Sep 3